Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia
Year: 2026
Type: article
Abstract: Covalent Bruton tyrosine kinase inhibitors (cBTKis) are commonly used targeted agents in early lines of therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) 1,2 ; however, treatment following disease progression on cBTKis remains a challenge in clinical practice.3,4 Venetoclax is a B-cell lymphoma-2 inhibitor approved for CLL and SLL treatment, either as continuous monotherapy or as a fixed-treatment duration (FTD) regimen in combination with anti-CD20 antibodies (FTD Ven+anti-CD20; frontline, 12 months; relapsed/refractory, 24 months). 4,5enetoclax has demonstrated durable responses and outcomes among patients with previous cBTKi exposure, both in clinical trials (eg, M14 032 and VENICE-1) 6,7 and in real-world studies.[8][9][10][11][12][13][14][15] Although these prior analyses included a proportion of patients who discontinued their cBTKi due to disease progression, real-world evidence on venetoclax used specifically among patients who previously progressed on a cBTKi is limited.Although an analysis from the CLL Collaborative Study of Real-World Evidence (CORE) was conducted to assess clinical outcomes among patients who initiated venetoclax-based therapy after having stopped cBTKi for a variety of reasons (eg, intolerance and disease progression), it did not explicitly focus on patients treated with FTD Ven+anti-CD20 in post-cBTKi progression settings nor did it assess overall survival (OS).13 With the expanding CLL and SLL treatment landscape, most recently with the availability in the post-cBTKi setting of the noncovalent BTKi pirtobrutinib, 4 there is a need for real-world evidence on existing therapies such as FTD Ven+anti-CD20 after previous cBTKi progression.Therefore, this study was conducted to assess
Source: Blood Neoplasia
Authors: Isabelle Fleury, Brian T. Hill, Toby A. Eyre, Chaitra Ujjani, Beenish S. Manzoor, Jennifer R. Brown, Hande H. Tuncer, Nicole Lamanna, Catherine C. Coombs, Nilanjan Ghosh, Lori A. Leslie, Lindsey E. Roeker, Nicolas Martinez-Calle, Paul M. Barr, Matthew S. Davids, Nnadozie Emechebe, Joanna M. Rhodes, Alan P. Skarbnik, Wendy Sinai, Laurie Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Bita Fakhri, Meghan C. Thompson, Deborah M. Stephens, Stephen J. Schuster, Michael Coyle, Andres Chang, Nancy Kaddis, Irina Pivneva, Annie Guerin, Mazyar Shadman
Institutions: Centre hospitalier universitaire de Québec, Centre hospitalier de l'Université Laval, Université Laval, Cleveland Clinic, Churchill Hospital, University of Oxford, Fred Hutch Cancer Center, AbbVie (United States), Dana-Farber Cancer Institute, Columbia University, University of California, Irvine, Levine Cancer Institute, Hackensack Meridian Health, Mayo Clinic, Nottingham University Hospitals NHS Trust, University of Rochester Medicine, University of Rochester, Rutgers Cancer Institute, Novant Health, University of Massachusetts Chan Medical School, Dartmouth–Hitchcock Medical Center, Tufts Medical Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Stanford Cancer Institute, Stanford University, Memorial Sloan Kettering Cancer Center, Abramson Cancer Center, University of Pennsylvania, Lowell General Hospital, Winship Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
OpenAlex ID: W7171516193